医学
误传
肺炎
重症监护医学
平衡(能力)
梅德林
2019年冠状病毒病(COVID-19)
2019-20冠状病毒爆发
医疗急救
风险评估
作者
Julio A. Ramirez,Barbara Ellen Jones,Eyal Oren,Nilam J. Soni,Marcos I. Restrepo,Daniel M. Musher,Brian L. Erstad,Chiagozie Ifeoma Pickens,Scott A. Helgeson,Kristina A. Crothers,Joshua P. Metlay,Britany Bissell,Bin Cao,James Duncan Chalmers,Charles S. Dela Cruz,Stephen Y. Liang,GRANT W. WATERER,Marilynn Paine,Conall J. Hawkins,Kevin C. Wilson
摘要
To the Editor—We are deeply saddened that IDSA did not endorse the 2025 Clinical Practice Guidelines Update for Community-Acquired Pneumonia (CAP) [1, 2]. The update was approved by an equal number of clinical experts appointed by ATS and IDSA, along with 5 nonvoting methodologists and 2 patients after months of careful review of the evidence, discussion, and consensus. We are concerned that for future guideline collaborations with IDSA evaluating antibiotic use, achieving an “appropriate balance,” as suggested by Klompas et al may prove difficult if judgments about antibiotic use are driven primarily by stewardship perspectives. IDSA's statements that the recommendations are not evidence based and that they will increase antibiotic use are incorrect. Guideline panels and clinicians must make decisions for patients regardless of how many high-quality trials are available. The committee recognized a lack of high-quality evidence in the form of comparative trials. As a result, our recommendations are conditional (ie, not appropriate for a sizable minority of patients), and we emphasized the importance of individualization of care. In the absence of randomized controlled trials, the best available evidence may consist of observational studies, case series, and clinical experience; this is still considered evidence [3]. Previous guidelines recommend treating all people with pneumonia with antibiotics regardless of the result of viral tests, due to concerns about bacterial–viral coinfection [4]. While this risk cannot be ignored, we seriously considered the uncertainty of this risk due to imperfect diagnostic tools, lack of outcomes studies, and the heterogeneity and uncertainty in both the benefit and harm of antibiotics for different patients. As a result of this deliberation, the ATS guidelines are the first to suggest withholding antibiotics for a population of adults with CAP: those with mild disease and no comorbidities. This recommendation, along with approval of lung ultrasound to diagnose pneumonia and shorter duration of therapy for people with pneumonia reaching clinical stability, stands to dramatically reduce, not increase, the use of antibiotics and should be recognized as an advance for stewardship.
科研通智能强力驱动
Strongly Powered by AbleSci AI